Comparing BioAtla (NASDAQ:BCAB) & Zealand Pharma A/S (OTCMKTS:ZLDPF)

BioAtla (NASDAQ:BCAB) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Analyst Ratings

This is a summary of recent ratings for BioAtla and Zealand Pharma A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1	0	1	0	2.00
Zealand Pharma A/S	0	8	1	2	2.45

BioAtla presently has a consensus price target of $200.00, suggesting a potential upside of 16,160.16%. Given BioAtla’s higher probable upside, analysts plainly believe BioAtla is more favorable than Zealand Pharma A/S.

Profitability

This table compares BioAtla and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-289.67%
Zealand Pharma A/S	58.86%	17.56%	16.17%

Valuation & Earnings

This table compares BioAtla and Zealand Pharma A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$8.50 million	0.24	-$59.61 million	($25.45)	-0.05
Zealand Pharma A/S	$1.40 billion	1.77	$977.29 million	$6.03	5.72

Zealand Pharma A/S has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

77.2% of BioAtla shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

BioAtla has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Summary

Zealand Pharma A/S beats BioAtla on 11 of the 14 factors compared between the two stocks.

About BioAtla

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.